The hypothesis that hepatocellular proliferative changes give rise to autonomous, neoplastic lesions in rodents was tested in this study in which hepatopro-!iferative lesions induced in rats by feeding an experimental psychoactive drug, cyproximide, were examined at various times during the course of a 24 month study. A total of 1610 male and female rats (Charles River Laboratories COBS@CD®(SD)BR, Wilmington, Mass.) were distributed into three groups. Each of two treatment groups contained 230 rats given 0.1% or 0.4% of cyproximide in the diet. One hundred and fifty rats were given a drug-free diet and served as controls. Five males and five females from each group were sacrificed for postmortem examination after 6, 12 and 20 months of drug diet feeding after which remaining rats were retained for recovery (nontreatment) periods of 18, 12 and 4 months, respectively. An additional 25 males and 25 females from each dose level were treated for 24 months and then sacrificed along with all surviving recovery and control rats. The results of this study demonstrated that the incidence of proliferative lesions was greater in the liver of treated rats (especially females) than in control rats; however, the incidence of hepatocellular neoplasms was the same in treated and control rats.
INTRODUCTION
Kinosita (1) , in 1955, described what he had observed as the earliest hepatocellular changes preceding neoplastic lesions in rats given butter yellow, p-dimethylaminoazobenzene (DAB). These changes consisted of focal and nodular formations of altered basophilic hepatocytes which interrupted the usual hepatic architecture and often compressed the surrounding normal hepatic cords. At the Presented at the International Symposium of the Society of Toxicologic Pathologists, Reston. Virginia, May 10-12,1982. 'Received 8/20/82. 2A porton of the data was presented at the International Symposium of the Society of Toxicologic Pathologists, May [10] [11] [12] [13] 1982 . Reston, Virginia.
"To whom reprint requests should be sent. 'Xenos, North Branch, New Jersey 08876. same conference of the National Cancer Institute, Firminger (2) described changes similar to those observed by Kinosita (1) and felt that the altered hepatocytes were the earliest evidence of neoplastic lesions induced by hepatocarcinogens. The data from those reports gave the first indication that hepatocellular carcinomas can arise from altered pre-neoplastic hepatocytes without the formation of cirrhosis. It seemed, at that time, that the histogenesis of hepatocellular carcinomas from islands or nodules of altered hepatocytes was certain, at least for some hepatocarcinogens. The question of whether or not some liver cancers arise from biliary structures in the rat is still under debate since neoplasms of the common bile duct have not been observed in rats according to Stewart, et. al. (3) . TOXICOLOGIC PATHOLOGY In addition, Squire and Levitt (4) did not recognize neoplasms of intrahepatic bile ducts, nor did the Institute of Laboratory Animal Resorces (lLAR) in a more recent publication (5) .
From the work of other investigators such as Jackson and Dessau (6) , who fed rats acetamide and described "disseminated foci" which preceeded trabecular carcinomas of the liver, the evidence seemed clear that hepatoproliferative nodules were the first signs of carcinoma induced by hepatocarcinogenic chemicals.
Investigators in the chemical and pharmaceutical industries began to report the occurrence of proliferative foci and nodules, morphologically similar to those which had been described during hepatocarcinogenesis in rodents treated with organochlorine insecticides such as DDT (7) and drugs such as phenobarbital (8) . Two important facts that have surfaced about these chemically induced nodules are first, they are observed in rodents treated with compounds that usually cause induction of hepatic microsomal mixed function oxidases, and second, the hepatoproliferative lesions almost always occur late in the life of the rodent, in contrast to carcinogen induced nodules which have an early time of onset. However, the proliferative foci or nodules are morphologically identical whether they are produced by carcinogens such as DAB or by other chemicals.
Based on this evidence, chemically induced hepatoproliferative foci and nodules in rodents have been interpreted as positive evidence of: 1) carcinogenic potential, and 2) carcinogenic risk to humans.
The purpose of this report is to present data from two chronic studies of 24 months duration in rats fed cyproximide. The first study was a routine bioassay designed to determine oncogenic potential; the second study was designed to elucidate the potential hepato-oncogenicity of cyproximide by attempting to answer the following questions: 1) what is the dose-time threshold for production of proliferative changes in liver parenchymal cells, and 2) if cyproximde is given at maximum tolerated doses for 20 months to allow for formation of liver nodules, do these nodules progress to cancer after discontinuation of the drug, i.e., do the nodules show autonomous growth?
METHODS
The chemical name and structure of cyproximide, an experimental psychoactive agent, are shown in Figure 1 . The design of two chronic studies in 1070 rats (Charles River COBS®CD®(SD)BR) is shown in Tables I and  II . Four hundred and sixty rats were used in the first bioassay. It is evident from these tables that the design of the second study included portions of the first study in that rats were fed 0.1% and 0.4% dietary levels of cyproximide daily for 24 months. The design of the second study is graphically presented in Figure 2 and shows the distribution of 610 rats into nine groups (eight treatment groups and one control group) based on duration of treatment and recovery. Five males and five females from each group, including controls, were sacrificed for postmortem examination after 6, 12 and 20 months in order to determine the status of the liver prior to discontinuation of the drug diet.
Unless otherwise stated, the data and conclusions presented are derived from the second of two chronic bioassays in which recovery segments were designed.
All rats were individually housed in wire bottom cages, maintained in environmentally controlled rooms at 22 ± 2°C and 55 ± 5% relative humidity with 12 hour light/dark cycles, and tap water was provided ad libitum.
Drug diet mixtures were prepared weekly throughout the study. Drug concentrations in the feed represented either 0.1% or 0.4% cyproximide, for the female animals. Male animals were given the same drug concentration in the diet until actual food intake fell to 90% of the female food intake. Drug concentrations were then increased for the male animals to approximate the current female drug intake. Body weights and food consumption were measured weekly. (1 pm) were stained with toluidine blue 0 and examined to define areas of interest, after which thin sections (70-80 nm) were cut, stained with urynal acetate and lead citrate, and examined in a Philips 200 electron microscope. For energy dispersive x-ray analysis, unstained sections (100 nm) were placed in a sample holder made of spectrographically pure carbon, and were analyzed in a JEOL JSM-U3 scanning electron microscope using the scanning transmission mode at a voltage of 25 kV and specimen current of 1.5 X 10-10 Amps, using a Nuclear Semiconductor retractable 6 mm diameter Si(Li) detector having a resolution of 152 eV at 5.94 KeV. Detector to specimen distance was 1.2 mm with an x-ray takeoff angle of 37 degrees. Data storage and handling were performed on a Tracor Northern NS-880 system.
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Biological Profile
Pharmacologically, cyproximide was classed as an anxiolytic with mild psychostimulant and/or antidepressant activity in animals and was not a monoamine oxidase inhibitor.
Pharmacokinetic studies were performed in the rat, dog, rabbit and squirrel monkey. The compound was shown to be rapidly and well absorbed with peak plasma concentrations of parent drug in 'less than 4 hours. The compound half-life was found to be relatively long, 3-7 days in the various species tested with 18-65% of the parent compound present for prolonged periods of time in the rat and dog. The compound was excreted primarily in the urine in all species tested; however, between 20-30% was found in the feces of the rat and squirrel monkey, as compared with In assessing microscopic changes in the liver, we arbitrarily classified lesions as: 1) nonproliferative changes which included hepatocellular hypertrophy, cytoplasmic vacuolization and cytoplasmic pigment deposition; and 2) hepatoproliferative changes which included altered foci or areas of light staining hepatocytes, basophilic areas or foci, hyperplastic foci, hyperplastic nodules and hepatocellular trabecular carcinomas. This classification was used for all animals whether they died early, were sacrificed prior to discontinuation of the drug diet, or were sacrificed at the termination of the study.
For light microscopy, livers were preserved in either Helly's fluid (Zenker-formal) or 10% unbuffered formalin, dehydrated, embedded in paraffin, cut at 6 JLm, and stained with hematoxylin and eosin. For electron microscopy, 1 mm" samples of liver were fixed in 2.5% glutaraldehyde in Sorensen's phosphate buffer (pH 7.4), washed in buffer, post fixed in 1% phosphate buffered osmium tetroxide, dehydrated, and embedded in Epon 812. Thick These data exclude recovery rats.
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survival was not severely compromised by toxic effects at either of two dose levels.
FIG. 4-Survival of female rats fed cyproximide vs controls p = 0.262 by the Breslow procedure (10). These data exclude recovery rats.
Morphologic Findings
Hepatomegaly, as judged from liver to body weight ratio, was seen after 6 and 12 months in rats fed 0.4% cyproximide. This finding was in agreement with data from the first bioassay, in which hepatomegaly was observed in rats fed 0.4% of cyproximide as early as 3 months. The enlargement of the liver was associated with enlarged centrolobular hepatocytes in which the cytoplasm showed dis-5% in the rabbit and dog. Over a period of approximately 2 weeks, 78-97% of the administered dose was recovered from all four species tested.
The acute toxicity of cyproximide is relatively low, with an LD w of 1600 mg/kg in the rat and 375 rug/kg in the mouse. Drug induced mortality occurred 2-6 days following the administration of a single oral dose.
Subacute studies were performed in both the rat and dog. In the rat, liver cell enlargement was seen at 2 weeks following the dietary administration of cyproximide at a 0.4% level. After 30 days, rats treated with either 0.1 or 0.3% of the compound demonstrated increased plasma transaminases, alkaline phosphatase and urea nitrogen levels. In dogs tteated for 5 weeks toxic signs were noted at 600 mg/kg, but animals survived at 900 mg/ kg.
Chronic studies in dogs at dosage levels up to 200 mg/kg produced increased liver weights after 3 months, but there were no hepatocellular alterations seen microscopically. Several chronic rat studies were performed prior to the initiation of the present study including the first 2 year bioassay with interim sacrifices at 3, 6, 12 and 18 months. An important finding from this 2 year experiment was the absence of neoplastic nodules prior to 18 months.
Teratology studies in rats and rabbits were negative. Several additional studies in rats were performed, the results of which indicated increased toxicity associated with one isomeric form of cyproximide (a racemic mixture) and in a second study, gavage administration was found to be only slightly more pharmacologically active than dietary administration.
Mortality
The estimated probability of survival for control rats and those fed 0.1% and 0.4% cyproximide for the duration of the study is shown in Figures 3 (males) and 4 (females). Included in these Figures are mean and median survival times for each group. The curves were constructed from data generated by life table estimates of the probability of survival using the Kaplan-Meier method, (9) and the Breslow procedure (10) was used to test for difference among survival curves. There was no statistically significant difference between treated and control rats (males, p == 0.559; females, p == 0.262). These data show that ruption of basophilic material and the nuclei were enlarged with prominent nucleoli. Electron microscopic examination revealed proliferated smooth endoplasmic reticulum in the enlarged hepatocytes.
After 6 months or more of treatment, vacuoles were seen in enlarged hepatocytes of males ( Figure 5 ), and birefringent pigment deposition was observed in enlarged hepatocytes of females ( Figure 6 ). Electron microscopic examination of hepatocytes from males revealed tightly packed swirls of smooth membrane or myelin figures associated with lipid material (Figure 7 ) that corresponded to the vacuoles seen by light microscopy. Electron microscopic examination of hepatocytes from females revealed pleomorphic, electron dense deposits (Figure 8 ) that corresponded to the pigment seen with the light microscope. These deposits contained electron lucid, needle-like areas with the ultrastructural appearance of porphyrin (11) (Figure 9 ). Elemental analysis of these deposits demonstrated the presence of iron and calcium ( Figure 9 ).
The centrolobular hypertrophy of hepatocytes, the vacuolation and the pigment deposition occurred in a dose related fashion in rats fed both 0.1% and 0.4% of cyproximide, and these changes tended to be reversible in rats permitted to recover from treatment for 4,12 and 18 months.
The distribution of hepatoproliferative changes is shown in Figures 10 (males) and 11 (females) for control rats and for rats fed 0.1% or 0.4% of cyproximide for 24 months. Statistical analyses of these data using a method described by Peto (12) showed only two findings with statistically significant differences compared to controls: foci of light staining hepatocytes (LSH) were decreased in males fed 0.4% of cyproximide and hyperplastic nodules (HN) were increased in females fed 0.4% of cyproximide (Table III) . In both males and females, a trend was seen toward a dose-related increase in the frequency of hyperplastic nodules. The incidence of hepatocellular carcinoma in treated rats was not significantly different from control rats.
If all groups of rats with nodules are analyzed, those in which rats were treated for 24 months and those in which rats were treated for various times and allowed to recover, the probability of developing nodules estimated by the method described by Hoel and Walburg (13) is shown in Table IV . These data show trends for nodules to develop over a 4 month span (20 to 24 months) in females fed 0.1% and 0.4% of cyproximide and at 24 months in males fed 0.1% and 0.4% of cyproximide; although the probability of developing nodules appears to be greater in males recovering for 6 and 12 months, this is in contrast to the consistently greater susceptibility of females to develop nodules.
At the time this study was conducted (between 1973 and 1975), the terminology for hepatoproliferative lesions was still under discussion.
As a result, descriptive terminology was used to define proliferative lesions and they were classified as follows: 1. Foci of light staining hepatocytes ( Figure  FIG 12) were characterized as relatively small foci containing hepatocytes with tinctorial qualities different from surrounding hepatocytes with which they were somewhat contiguous. These foci were distinct but not well delineated from the surrounding architecture and they would correspond to clear cell, eosinophilic or ground glass foci of hepatocellular alteration in currently used terminology. 2. Basophilic foci ( Figure 13 ) were relatively small foci of hepatocytes in which the cytoplasm was more basophilic than that of the surrounding tissue. These cells were contiguous with adjacent hepatocytes and were easily distinguished from the surrounding architecture and correspond to basophilic foci in the currently used terminology. 3. Hyperplastic foci (Figure 14) were larger than the foci of light staining hepatocytes and tended to disrupt surrounding architecture; cells were usually smaller. having either basophilic or eosinophilic cytoplasma. There is no correspondence of these lesions to currently used terminology and they were distinguished from nodules on the basis of lack of compression of surrounding liver cords. 4. Hyperplastic nodules ( Figure 15 ) contained cells similar to those of hyperplastic foci, but tended to compress surrounding liver cords. Current usage for these lesions is neoplastic nodule or hepatocellular adenoma and they correspond to disseminated foci described by Jackson and Dessau (6) . 5. Hepatocellular carcinomas ( Figure 16 ) were always moderately-to-well differentiated neoplasms with trabecular patterns which tended to encroach upon surrounding nonneoplastic liver; metastases were not seen but one carcinoma invaded blood vessels. Since only hyperplastic nodules were increased over controls in rats fed cyproximide, it seemed useful to look at the distribution of both hyperplastic nodules and hepatocellular carcinoma for all animals. These data are presented in Tables V (males) and VI (females) which show distribution of both nodules and carcinoma for all rats regardless of time of death, interim kills or terminal kills. Table VII shows the incidence of nodules and carcinomas as the percentage of: 1) rats examined at interim kills, 2) rats that died during the study, 3) rats at the terminal kill, and 4) all rats. In comparing the incidences of hyperplastic nodules in livers of females rats fed 0.4% of cyproximide from two studies, Figure 17 was constructed to show the cumulative incidence of nodules between 18 months and 24 months of continuous treatment. These data show that the high incidence of nodules (66%) seen in the first study was not attained in the second (recovery) study (32%), although the frequency was significantly different from controls in both studies. Also, the trends over time appear to be comparable when cumulative incidences are plotted.
DISCUSSION
The results of the present investigation showed that there appears to be no autonomy of hepatoproliferative lesions when rats treated for 24 months are compared to rats treated for 6, 12 and 20 months with cyproximide, in spite of a dose-related increase in nodules of treated versus control rats, especially females. No correlation was found among proliferative lesions, hyperplastic nodules and hepatocellular crcinoma, and nodules did not show autonomous progression. Rather the data indicated possible regression of many proliferative lesions over time. Non-proliferative changes, suggestive of hepatic microsomal enzyme induction, were reversible in rats allowed to recover from 6 and 12 months of treatment, and non-proliferative changes showed a trend toward reversibility in rats recovering for 4 months after 20 months of treatment. It would appear from the data generated in the present study that cyproximide is similar to compounds such as DDT and phenobarbital (7, 8) in its ability to promote the formation of hyperplastic nodules. The promotion of these nodules appears to be related to the pharmacologic property of induction of hepatic microsomal enzymes as proposed by Cohen and Grasso (14) .
In neither of the two bioassays with cyproximide in rats was there data to support the concept that hyperplastic nodules were either neoplastic or preneoplastic as has been shown for some hepatocarcinogens (1, 2) .
If the frequency of hepatocellular carcinoma is examined carefully, the data show a decreased incidence compared to controls for males fed cyproximide (5% in control vs 4% and 0% in low and high dose rats) and a slightly increased incidence in females fed cyproximide (0% in control vs 0% and 4% in low and high dose rats). As mentioned previously, neither difference was statistically significant. This observation appears to support the hypothesis that cyproximide induced nodules are not preneoplastic and it refutes the hypothesis that all nodules are either neoplastic in behavior, or at least preneoplastic.
In an investigation to study the reversibility of hepatocellular alterations, disseminated foci and hepatic tumors induced by acetamide, Jackson and Dessau (6) allowed rats to recover from treatment weekly for up to 1 year. They showed that removal of 5% drug diets in this manner produced an earlier onset 
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Interim kill (N)8 24 FIG. 17-Cumulative incidence of hyperplastic nodules in female rats fed 4.0% cyproximide. Comparison between two chronic bioassays to show different incidences, but a similar trend. In both studies the incidence of hyperplastic nodules showed a statistically significant difference from controls.
which the frequency of hepatocellular carcinomas was not increased.
It has been proposed that chemically induced hepatoproliferative lesions in rodents pose a risk of cancer to humans in that the increased frequency of these lesions is evidence for carcinogenic risk to humans. Conversely, the conclusion from data presented in a recent publication of the World Health Organization (15) was that more than 30 years after the introduction of DDT, there appears to be no evidence that DDT is carcinogenic in humans despite the fact that DDT induced hyperplastic nodules in rodent livers. Identical conclusions could be made from data compiled on other chemicals to which rodents and humans have been exposed (13) .
The hypothesis that an increased incidence of altered hepatocellular foci and of hyperplastic nodules is evidence for carcinogenic potential has been proposed because of investigations with chemical hepatocarcinogenesis and the effect of some chemicals in "promoting" or enhancing the induction of liver tumors, i.e., producing either a higher incidence or earlier onset of tumors than would be expected from administering a carcinogen alone. These promoters have been called epigenetic (vs genotoxic) carcinogens (16) , examples of which are phenobarbital (7) and some hypolipidemic agents (13) . Whether or not cyproximide is an enhancer of hepatocarcinogenesis in rodents is a subject for further investigation. That's all. The cellular proliferation looked about the same in both, but in one there was no evidence at all, as in the basophilic focus I showed you. If you make that a little bigger, it could even be a hyperplastic focus, but there was no compression in the surrounding liver at all. Those were our criteria for those two types.
DR. PAYNE: The nodule had compression and the focus did not. DR. SPARANO: That's right, Bobby. Yes. DR. de la IGLESIA: I have a question. I'm still trying to sort out in my mind the purpose or the experimental objective of having the recovery groups. I think it should be clear what the aim of having a recovery group is because if one is planning to have a recovery group those animals that are selected into that group should be examined to see whether they have liver tumors to begin with. Otherwise, the validity of the observation at the end isn't that relevant. If you're counting tumors only, if you're again back to the numbers game, which then ends up in a matrix like that, it is very difficult to interpret. The objective of recovery phases in these experimental designs ought to be very well defined.
DR. SPARANO: I agree with part of that but not with all of it, Dr. de la Iglesia. I think people during this meeting have showed that you don't necessarily have to look at the animals. If you've got what you think might be a stimulus during your study for autonomous growth, then take some of those animals off at different periods of time and see whether that drug induces autonomous growth. I think that is a fair way to proceed. I agree with you that we could have done a lot more, yes. We could have used larger numbers of animals and looked at those animals and opened them up, as some people have done, to see if they had nodules.
DR. de la IGLESIA: The premise is then therefore the hypothesis has to be-this drug has to produce 100%, of tumors to begin with. Otherwise, you may be putting into the recovery group some animals which have tumors and some which don't.
